A bidirectional Tet-dependent promotor construct regulating the expression of E1A for tight control of oncolytic adenovirus replication.

No abstract is available for this paper.

• Publication year

  2007

• Venue

  Journal of Biotechnology

• Publication date

  2007-01-20

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/J.JBIOTEC.2006.09.011PMID 17083991
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• An improved Tet-On regulatable FasL-adenovirus vector system for lung cancer therapy

  2006cited by this paper
• Tamoxifen-regulated adenoviral E1A chimeras for the control of tumor selective oncolytic adenovirus replication in vitro and in vivo

  2006cited by this paper
• Oncolytic virotherapy for cancer treatment: challenges and solutions

  2005cited by this paper
• Oncolytic adenovirus that overproduces ADP and replicates selectively in tumors due to hTERT promoter-regulated E4 gene expression

  2005cited by this paper
• Future prospects for oncolytic therapy

  2005cited by this paper
• Late Expression of Nitroreductase in an Oncolytic Adenovirus Sensitizes Colon Cancer Cells to the Prodrug CB1954

  2005cited by this paper
• Tight control of transgene expression by lentivirus vectors containing second‐generation tetracycline‐responsive promoters

  2005cited by this paper
• Viral and nonviral factors causing nonspecific replication of tumor- and tissue-specific promoter-dependent oncolytic adenoviruses.

  2005cited by this paper
• Second‐generation tetracycline‐regulatable promoter: repositioned tet operator elements optimize transactivator synergy while shorter minimal promoter offers tight basal leakiness

  2004cited by this paper
• A novel tetracycline-controlled transactivator–transrepressor system enables external control of oncolytic adenovirus replication

  2003cited by this paper
• Tight control of gene expression by a helper-dependent adenovirus vector carrying the rtTA2s-M2 tetracycline transactivator and repressor system

  2002cited by this paper
• New tools for the construction of replication-competent adenoviral vectors with altered E1A regulation.

  2002cited by this paper
• A system for small-molecule control of conditionally replication-competent adenoviral vectors.

  2002cited by this paper
• Tissue-Specific, Tumor-Selective, Replication-Competent Adenovirus Vector for Cancer Gene Therapy

  2001cited by this paper
• Creation of a new transgene cloning site near the right ITR of Ad5 results in reduced enhancer interference with tissue-specific and regulatable promoters

  2001cited by this paper
• Insulation from viral transcriptional regulatory elements improves inducible transgene expression from adenovirus vectors in vitro and in vivo

  2000cited by this paper
• Update on adenovirus and its vectors.

  2000cited by this paper
• Exploring the sequence space for tetracycline-dependent transcriptional activators: novel mutations yield expanded range and sensitivity.

  2000cited by this paper
• Trans-complementation of vector replication versus Coxsackie-adenovirus-receptor overexpression to improve transgene expression in poorly permissive cancer cells

  2000cited by this paper
• An adenovirus E1A mutant that demonstrates potent and selective systemic anti-tumoral efficacy

  2000cited by this paper
• Expression of Coxsackie adenovirus receptor and alphav-integrin does not correlate with adenovector targeting in vivo indicating anatomical vector barriers

  1999cited by this paper
• ‘Autoreplication’ of the vector genome in recombinant adenoviral vectors with different E1 region deletions and transgenes

  1999cited by this paper
• Identification of the transcriptional regulatory sequences of human kallikrein 2 and their use in the construction of calydon virus 764, an attenuated replication competent adenovirus for prostate cancer therapy.

  1999cited by this paper
• A Novel Tumor-Specific Replication-Restricted Adenoviral Vector for Gene Therapy of Hepatocellular Carcinoma

  1999cited by this paper
• A tetracycline controlled activation/repression system with increased potential for gene transfer into mammalian cells

  1999cited by this paper
• Graded transcriptional response to different concentrations of a single transactivator.

  1998cited by this paper
• Treatment of human brucellosis with netilmicin and doxycycline.

  1996cited by this paper
• An Adenovirus Mutant That Replicates Selectively in p53- Deficient Human Tumor Cells

  1996cited by this paper
• Transcriptional activation by tetracyclines in mammalian cells.

  1995cited by this paper
• Upstream Enhancer Activity in the Human Surfactant Protein B Gene Is Mediated by Thyroid Transcription Factor 1 (*)

  1995cited by this paper
• Tight control of gene expression in mammalian cells by tetracycline-responsive promoters.

  1992cited by this paper
• Functional diversity of E1A gene autoregulation among human adenoviruses

  1992cited by this paper
• Permanent cell line expressing human factor VIII-related antigen established by hybridization.

  1983cited by this paper

• Recent advances of engineered oncolytic viruses-based combination therapy for liver cancer

  2024cites this paper
• Chemogenetic ON and OFF switches for RNA virus replication

  2021cites this paper
• Systemic administration of mesenchymal stem cells loaded with a novel oncolytic adenovirus carrying IL-24/endostatin enhances glioma therapy.

  2021cites this paper
• Switching a Replication-Defective Adenoviral Vector into a Replication-Competent, Oncolytic Adenovirus

  2013cites this paper
• A Hoxb13‐driven reverse tetracycline transactivator system for conditional gene expression in the prostate

  2012cites this paper
• Viral Vectors for RNA Interference Applications in Cancer Research and Therapy

  2011cites this paper
• Development of Chimeric Gene Regulators for Cancer-specific Gene Therapy with both Transcriptional and Translational Targeting

  2010cites this paper
• Systèmes d'expression régulée

  2010cites this paper
• Cellular targeting for cochlear gene therapy.

  2009cites this paper
• Efficient and selective tumor cell lysis and induction of apoptosis in melanoma cells by a conditional replication‐competent CD95L adenovirus

  2009cites this paper
• RNA-Interferenz-vermittelte Gentherapie bei Herzinsuffizienz mittels Phospholamban-shRNA exprimierender adenoviraler und AAV–Vektoren

  2009cites this paper
• Mutant sodium channel for tumor therapy.

  2009cites this paper
• Turning the gene tap off; implications of regulating gene expression for cancer therapeutics

  2008cites this paper
• Apoptosis pathways and oncolytic adenoviral vectors: promising targets and tools to overcome therapy resistance of malignant melanoma

  2007cites this paper